Plunkett Research Online: CASI Pharmaceuticals Inc

CASI PHARMACEUTICALS INC (CASI:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products with a portfolio that includes approved and investigational assets. CASI’s first commercial product, EVOMELA (melphalan/injection) launched in.....



CASI Pharmaceuticals Inc
Ticker: CASI
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 240 864-2600
Fax: 240 864-2601
Address: 9620 Medical Center Drive
Suite 300
Rockville, MD 20850 United States

Types Of Business
Industry Ranks

Industry NAICS code:

Drugs-Angiogenesis
Drugs-Cancer & Rheumatoid Arthritis
ContactsDescription

Wei-Wu HeCEO/Chairman of the Board/Director
George ChiCFO/Chief Accounting Officer
See More
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products with a portfolio that includes approved and investigational assets. CASI’s first commercial product, EVOMELA (melphalan/injection) launched in.....See More See More

Auditor: KPMG Huazhen
Legal Advisor: Arnold & Porter LLP
$USD, In whole numbers,
except marked * or %
201920182017201620152014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and AffiliatesTop Salaries
EVOMELA
CID-103
ZEVALIN
NameTitleSalary (US$)Bonus (US$)
Other ThoughtsCorporate Culture

Apparent Female Officers or Directors: